Pertuzumab: beside a new treatment under test
83 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (50), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingNCT07857226Phase 2Report a problem
- Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingNCT07797218Phase 3Report a problem
- Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingNCT07795424Phase 2Report a problem
- Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739511Phase 1/2Report a problem
- Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingNCT07732491Phase 2Report a problem
- Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ AdenocarcinomaNot yet recruitingNCT07716111Phase 2Report a problem
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07716046Phase 2Report a problem
- Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingNCT07647263Phase 2Report a problem
- Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingNCT07616427Phase 2Report a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2Report a problem
- Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHPNot yet recruitingNCT07589699Phase 4Report a problem
- Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast CancerRecruitingNCT07581795Phase 2Report a problem
- Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.Not yet recruitingNCT07528898Phase 2Report a problem
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingNCT07518173Phase 3Report a problem
- Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLCNot yet recruitingNCT07377916Not applicableReport a problem
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingNCT07377643Phase 3Report a problem
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2Report a problem
- SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyNot yet recruitingNCT07307287Phase 2Report a problem
- A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNot yet recruitingNCT07294534Phase 2/3Report a problem
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingNCT07294508Phase 2/3Report a problem
- A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Not yet recruitingNCT07290166Phase 2Report a problem
- Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2Report a problem
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBCNot yet recruitingNCT07245797Phase 2Report a problem
- A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingNCT07140393Phase 1/2Report a problem
- Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract CancerNot yet recruitingNCT07129018Phase 2Report a problem
- HB1801 Combined Treatment of HER2-positive Breast CancerNot yet recruitingNCT07116824Phase 2Report a problem
- Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast CancerNot yet recruitingNCT07093931Phase 4Report a problem
- Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNot yet recruitingNCT07047755Phase 2Report a problem
- This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.Not yet recruitingNCT06973525Phase 2Report a problem
- SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2Report a problem
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Phase 2/3Report a problem
- Pyrotinib in HER2-positive Early Breast CancerNot yet recruitingNCT06718335Not applicableReport a problem
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingNCT06686394Phase 1/2Report a problem
- The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast CancerRecruitingNCT06641544Phase 4Report a problem
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT06555068Phase 1/2Report a problem
- Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)Not yet recruitingNCT06510465Phase 2Report a problem
- Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast CancerRecruitingNCT06276868Phase 2Report a problem
- DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerRecruitingNCT06178159Phase 2Report a problem
- Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNot yet recruitingNCT05983094Phase 2Report a problem
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingNCT05978648Phase 2Report a problem
- Thero2-01S22 in HER2-positive Breast CancerNot yet recruitingNCT05698186Phase 3Report a problem
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabRecruitingNCT05325632Phase 2Report a problem
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingNCT05306041Phase 2Report a problem
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2Report a problem
- RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingNCT05256745Phase 1/2Report a problem
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Phase 1/2Report a problem
- Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT04973319Phase 3Report a problem
- Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HPNot yet recruitingNCT04929548Phase 4Report a problem
- Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2Report a problem
- Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerRecruitingNCT04329065Phase 2Report a problem
- Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT05954143Phase 2Results postedReport a problem
- MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingNCT04425018Phase 2Results postedReport a problem
- Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast CancerCompletedNCT03112590Phase 1/2Results postedReport a problem
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT03101748Phase 1/2Results postedReport a problem
- Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyCompletedNCT01922921Phase 1/2Results postedReport a problem
- A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast CancerCompletedNCT00951665Phase 1/2Results postedReport a problem
- A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast CancerCompletedNCT00934856Phase 1/2Results postedReport a problem
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingNCT06771622Phase 1/2Report a problem
- A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06445400Phase 2Report a problem
- A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerActive, not recruitingNCT06057610Phase 3Report a problem
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerTerminatedNCT06038539Phase 3Report a problem
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruitingNCT05593094Phase 1/2Report a problem
- Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2Report a problem
- A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast CancerStatus unknownNCT05483439Phase 2Report a problem
- A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020TerminatedNCT05385705Phase 1Report a problem
- A Phase Ib/II Study of SHR-A1811 Injection in Breast CancerStatus unknownNCT05353361Phase 2Report a problem
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingNCT05296798Phase 3Report a problem
- Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2Report a problem
- Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsCompletedNCT04253561Phase 1Report a problem
- TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing CancerCompletedNCT04246671Phase 1Report a problem
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownNCT04197687Phase 2Report a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1Report a problem
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast CancerCompletedNCT03387553Early Phase 1Report a problem
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1Report a problem
- Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast CancerCompletedNCT02909751Phase 2Report a problem
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1Report a problem
- Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1Report a problem
- Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerCompletedNCT02390427Phase 1Report a problem
- A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCISWithdrawnNCT02336984Phase 1/2Report a problem
- Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerCompletedNCT02060253Phase 1Report a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingNCT02057133Phase 1Report a problem
- A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 ProteinCompletedNCT01918254Phase 1Report a problem
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2Report a problem